Vertaling van "monitoring response to treatment " (Nederlands → Frans) :

Referenties (4) Louis Harris Interactive research, 2002 (14) Mulhall JP et al. Erectile dysfunction: Monitoring response to treatment in clinical practice-recommendations of an international study panel.
Références : (4) Louis Harris Interactive research, 2002 (14) Mulhall JP et al. Erectile dysfunction: Monitoring response to treatment in clinical practice-recommendations of an international study panel.

In the Board of Directors, the Audit and Compliance Committee is responsible for monitoring regular audits of corporate citizenship implementation and compliance.
Au sein du Conseil d’administration, c’est le Comité d’Audit et de Conformité qui est chargé de faire contrôler la bonne application, sur le terrain, de nos principes citoyens.

The Production & Distribution department of the FAMHP is responsible firstly for overseeing the conformity to current standards, guidelines and legal requirements for the manufacture, distribution and dispensing of medicines and health products and secondly for granting authorisations, recognitions and certificates, as well as for combating illegal practices and monitoring pharmacies.
The Production & Distribution department of the FAMHP is responsible firstly for overseeing the conformity to current standards, guidelines and legal requirements for the manufacture, distribution and dispensing of medicines and health products and secondly for granting authorisations, recognitions and certificates, as well as for combating illegal practices and monitoring pharmacies.

Deze webpagina's ondersteunen de registratie van de Treatment Demand Indicator in België (een project van het European Monitoring Centre for Drugs and Drug Addiction, EMCDDA).
Ces pages web supportent l'enregistrement du Treatment Demand Indicator en Belgique (un projet de l'European Monitoring Centre for Drugs and Drug Addiction, EMCDDA).

This diagnostic is expected to help physicians optimize treatment of patients with CML, indicating the depth of patients’ response to tyrosine kinase inhinitor (TKI) treatments.
Ce test devrait optimiser le traitement des malades atteints de LMC en indiquant le degré de leur réponse aux traitements par un inhibiteur de tyrosine kinase (ITK).

of qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and quantitative (COBAS AMPLICOR HCV monitor 2.0 versus VERSANT HCV RNA 3.0) assays for hepatitis C virus (HCV) RNA detection and quantification: impact on diagnosis and treatment of HCV infections.
quantitative (COBAS AMPLICOR HCV monitor 2.0 versus VERSANT HCV RNA 3.0) assays for hepatitis C virus (HCV) RNA detection and quantification: impact on diagnosis and treatment of HCV infections.

Pharmaceuticals – Corthera On February 3, Novartis completed the acquisition of the privately held US based Corthera Inc., gaining worldwide rights to Relaxin for the treatment of acute decompensated heart failure and assumed full responsibility for development and commercialization for a total purchase consideration of USD 327 million.
Pharmaceuticals – Corthera Le 3 février, Novartis a achevé l’acquisition de Corthera Inc., une entreprise américaine non cotée, pour un prix total d’USD 327 millions.

included in the previous set as a sustainability indicator, showing the system’s capacity to be responsive to emerging needs. However, treatments reimbursed by
included in the previous set as a sustainability indicator, showing the system’s

Tabel 5 Sustained Virologic Response (SVR), End of Treatment (EOT) en Relapse bij niet eerder behandelde deelnemers (early en late responders)
Tableau 5 Réponse virologique prolongée (RVP), Fin De Traitement (FDT) et Taux de Rechutes † chez les patients non préalablement traités (répondeurs rapides et lents)

De secundaire eindpunten omvatten progressievrije overleving (progression-free survival, PFS), objectieve mate van respons (objective response rate, ORR), mate van klinisch voordeel, tijd tot het falen van de behandeling (time to treatment failure, TTF), en de ”quality adjusted survival”-meting.
Les critères secondaires étaient la survie sans progression (SSP), le taux de réponse objective (RO), le taux de bénéfice clinique, le temps jusqu'à échec thérapeutique (TET) et la survie ajustée selon la qualité de vie.